345 related articles for article (PubMed ID: 32040157)
1. Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.
Okumura G; Iguchi-Manaka A; Murata R; Yamashita-Kanemaru Y; Shibuya A; Shibuya K
J Exp Med; 2020 Mar; 217(4):1. PubMed ID: 32040157
[TBL] [Abstract][Full Text] [Related]
2. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
[TBL] [Abstract][Full Text] [Related]
3. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
[TBL] [Abstract][Full Text] [Related]
4. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
[TBL] [Abstract][Full Text] [Related]
5. Increased Soluble CD155 in the Serum of Cancer Patients.
Iguchi-Manaka A; Okumura G; Kojima H; Cho Y; Hirochika R; Bando H; Sato T; Yoshikawa H; Hara H; Shibuya A; Shibuya K
PLoS One; 2016; 11(4):e0152982. PubMed ID: 27049654
[TBL] [Abstract][Full Text] [Related]
6. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
7. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB; Matosevic S
J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
[TBL] [Abstract][Full Text] [Related]
8. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
9. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
[TBL] [Abstract][Full Text] [Related]
10. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
11. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
12. High expression of soluble CD155 in estrogen receptor-negative breast cancer.
Iguchi-Manaka A; Okumura G; Ichioka E; Kiyomatsu H; Ikeda T; Bando H; Shibuya A; Shibuya K
Breast Cancer; 2020 Jan; 27(1):92-99. PubMed ID: 31372841
[TBL] [Abstract][Full Text] [Related]
13. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ
J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517
[TBL] [Abstract][Full Text] [Related]
14. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
[TBL] [Abstract][Full Text] [Related]
15. Contribution of inhibitory receptor TIGIT to NK cell education.
He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
[TBL] [Abstract][Full Text] [Related]
16. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.
Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A
Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389
[TBL] [Abstract][Full Text] [Related]
17. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
Lakshmikanth T; Burke S; Ali TH; Kimpfler S; Ursini F; Ruggeri L; Capanni M; Umansky V; Paschen A; Sucker A; Pende D; Groh V; Biassoni R; Höglund P; Kato M; Shibuya K; Schadendorf D; Anichini A; Ferrone S; Velardi A; Kärre K; Shibuya A; Carbone E; Colucci F
J Clin Invest; 2009 May; 119(5):1251-63. PubMed ID: 19349689
[TBL] [Abstract][Full Text] [Related]
18. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
[TBL] [Abstract][Full Text] [Related]
19. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.
Okumura G; Abe F; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):135-139. PubMed ID: 28498033
[TBL] [Abstract][Full Text] [Related]
20. DNAM-1 controls NK cell activation via an ITT-like motif.
Zhang Z; Wu N; Lu Y; Davidson D; Colonna M; Veillette A
J Exp Med; 2015 Nov; 212(12):2165-82. PubMed ID: 26552706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
